Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma

The efficacy of nivolumab is greater than that of other anti-melanoma drugs, so nivolumab-based combined therapies that enhance anti-tumor immune responses in patients with metastatic melanoma are of great interest to dermato-oncologists. As we have previously reported, IFN-β enhances the anti-tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimura, Taku, Hidaka, Takanori, Kambayashi, Yumi, Furudate, Sadanori, Kakizaki, Aya, Tono, Hisayuki, Tsukada, Akira, Haga, Takahiro, Hashimoto, Akira, Morimoto, Ryo, Yamaguchi, Takuhiro, Takano, Tadao, Aiba, Setsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642629/
https://www.ncbi.nlm.nih.gov/pubmed/29050354
http://dx.doi.org/10.18632/oncotarget.17090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642629/
https://www.ncbi.nlm.nih.gov/pubmed/29050354
http://dx.doi.org/10.18632/oncotarget.17090

Ejemplares similares